GSK
GSK
895 hedge funds and large institutions have $13.5B invested in GSK in 2019 Q4 according to their latest regulatory filings, with 144 funds opening new positions, 296 increasing their positions, 287 reducing their positions, and 45 closing their positions.
220% more first-time investments, than exits
New positions opened: 144 | Existing positions closed: 45
28% more call options, than puts
Call options by funds: $163M | Put options by funds: $128M
14% more funds holding in top 10
Funds holding in top 10: 14 → 16 (+2)
12% more capital invested
Capital invested by funds: $12.1B → $13.5B (+$1.47B)
11% more funds holding
Funds holding: 806 → 895 (+89)
3% more repeat investments, than reductions
Existing positions increased: 296 | Existing positions reduced: 287
0.1% more ownership
Funds ownership: 4.53% → 4.62% (+0.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$301M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$141M |
| 3 |
Renaissance Technologies
New York
|
+$65.7M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$40.7M |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$37.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$86.6M |
| 2 |
Two Sigma Investments
New York
|
-$57.8M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$32.6M |
| 4 |
Jane Street
New York
|
-$32M |
| 5 |
BHC
Bowen Hanes & Co
Ponte Vedra Beach,
Florida
|
-$30.6M |
GSK Hedge Fund Activity: Q4 2019 in Review
895 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2019, worth a combined $13.5B — up 12% from $12.1B a quarter earlier.
Buyers outnumbered sellers: 144 funds opened new GSK positions and 45 closed out — a net gain of 99 holders — while 296 added to existing stakes and 287 trimmed.
The largest buyer was Boston Partners, adding an estimated $301M. The largest seller was Dodge & Cox, cutting an estimated $86.6M.
- 895 institutional investors held GSK (GSK) as of Q4 2019, up from 806 in Q3 2019.
- Funds reported $13.5B of GSK stock for Q4 2019, up 12% quarter-over-quarter.
- 144 funds opened new GSK positions in Q4 2019 and 45 closed out, a net change of +99 holders.
- The largest GSK buyer in Q4 2019 was Boston Partners, an estimated $301M added.
- The largest GSK seller in Q4 2019 was Dodge & Cox, an estimated $86.6M sold.
Based on aggregated 13F filings for Q4 2019.